TICKERNERD
Menu
COGTCOGTHealthcare · Biotechnology

COGT Stock Forecast: Cogent Biosciences, Inc. Price Predictions for 2026-2027

Last close, 2 Oct 2026
$31
−1.80% on the day

The 12 Wall Street analysts covering Cogent Biosciences, Inc. hold a median 12-month price target of $55 — +77.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 3 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.4B
Ticker Nerd rank
34 / 100
Median analyst target
$55
Analysts covering
12
Revenue$0.0
Operating income−$102.6M
Net income−$96.4M
Free cash flow−$77.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.0%
1M
−10.3%
YTD
−12.7%
1Y
+110.3%
From 52W high
−27.6%
From 52W low
+119.5%
$14
$43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

COGT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cogent Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
34 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
88
Value
70
Volatility
52
Revisions
48
Accruals
47
Quality
39
Growth
37
Size
22
Issuance
7

Momentum (88): The shares have been drifting up relative to others.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

COGT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on COGT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26COGTHigh $62Median $55Low $45

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
11 Buy1 Hold0 Sell
Low $45Median $55High $62

The green dot is the last close — the median target sits +77.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
16 Sept 2026WedbushReiteratesOutperform$55
15 Sept 2026HC Wainwright & Co.ReiteratesBuy$55
17 Aug 2026Piper SandlerMaintainsOverweight$52 → $55
17 Aug 2026Piper SandlerMaintainsOverweight—
12 Aug 2026GuggenheimMaintainsBuy$45 → $52
12 Aug 2026GuggenheimMaintainsBuy—
29 May 2026WedbushReiteratesOutperform$55
29 May 2026WedbushReiteratesOutperform—
6 May 2026HC Wainwright & Co.MaintainsBuy—
17 Mar 2026WedbushReiteratesOutperform—
16 Mar 2026JefferiesAssumesBuy$55
18 Feb 2026Piper SandlerMaintainsOverweight—
21 Jan 2026WedbushReiteratesOutperform—
6 Jan 2026HC Wainwright & Co.MaintainsBuy—
19 Dec 2025JP MorganMaintainsOverweight—
8 Dec 2025NeedhamReiteratesHold—
13 Nov 2025HC Wainwright & Co.MaintainsBuy—
11 Nov 2025BairdMaintainsNeutral—
10 Nov 2025Leerink PartnersMaintainsOutperform—
4 Nov 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. COGT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

COGT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 2 Oct 2026, Cogent Biosciences, Inc. returned +110.3% against +16.2% for the S&P 500, dividends included.

COGT vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26COGTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

COGT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
4
Fundamentals

Cogent Biosciences, Inc. (COGT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−15.2×

Cheaper than 95% of US stocks

Price / sales
—
Price / book
11.4×

Cheaper than 8% of US stocks

EV / EBITDA
−12.7×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−109.7%

Higher than 12% of US stocks

Return on assets
−43.8%

Higher than 9% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cogent Biosciences, Inc. (COGT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cogent Biosciences, Inc. has a market value of $5.4B and an enterprise value of $4.9B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$377.2M.

  • Diluted earnings per share, trailing twelve months: $−2.27.

  • Free cash flow in the twelve months to 30 June 2026: −$309.2M.

  • Shares outstanding: 171.6M.

  • Trailing P/E: −15.2×; forward P/E: −27.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Cogent Biosciences, Inc. employs 258 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

COGT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
COGTCogent Biosciences, Inc.$5.4B
34
CRSPCRISPR Therapeutics AG$5.3B
37
PTCTPTC Therapeutics, Inc.$5.3B
64
TVTXTravere Therapeutics, Inc.$5.4B
86
MIRMMirum Pharmaceuticals, Inc.$5.4B
66
ERASErasca, Inc.$5.0B
55
ORKAOruka Therapeutics, Inc.$5.6B
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cogent Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest COGT news & analysis

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

GlobeNewsWire · 15 Sept 2026positive

Cogent Biosciences announced that the FDA has accepted its New Drug Application for bezuclastinib in patients with advanced systemic mastocytosis (AdvSM). The application is supported by positive results from the APEX pivotal trial, which demonstrated clinically meaningful responses and evidence of disease modification.

Why it matters — FDA acceptance of the NDA moves bezuclastinib, a key pipeline candidate, one step closer to potential regulatory approval in AdvSM.

Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat

Seeking Alpha · 27 Aug 2026positive

Cogent Biosciences is positioned to commercialize bezuclastinib across three indications, with positive pivotal data in GIST, NonAdvSM, and AdvSM supporting three NDAs. Regulatory decisions are expected between late 2026 and early 2027, backed by the company's commercial infrastructure and $865.9M liquidity providing a runway through 2028.

Why it matters — A COGT watcher would care because the three upcoming regulatory decisions and the company's cash runway through 2028 represent key near-term milestones for the company's commercial launch potential.

Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks Investment Research · 13 Aug 2026positive

Zacks Investment Research noted that Cogent Biosciences (COGT) shares have formed a hammer chart pattern, suggesting the stock found support after recent declines. This technical indicator, combined with an upward trend in earnings estimate revisions, could signal a near-term trend reversal for the stock.

Why it matters — A COGT watcher would care because the technical chart pattern and improving earnings estimates may indicate the stock has stopped losing value and could be poised to move higher.

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

GlobeNewsWire · 10 Aug 2026positive

Cogent Biosciences reported second-quarter 2026 financial results, highlighting that it is on track for potential FDA approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30), and has submitted an AdvSM New Drug Application to the FDA. The company also reported a pro forma cash balance of $865.9 million, sufficient to fund operations into late 2028.

Why it matters — A COGT watcher would care because the company is approaching two major PDUFA dates later this year for bezuclastinib, which could be pivotal catalysts for the stock.

FAQ

Frequently asked questions about COGT stock

What is the COGT stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Cogent Biosciences, Inc. have a median 12-month price target of $55, with estimates ranging from $45 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is COGT stock a buy right now?

Of the 12 analysts covering Cogent Biosciences, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cogent Biosciences, Inc. 34 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank COGT?

As at 3 Oct 2026, Cogent Biosciences, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (88 of 100).

Will COGT stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +77.3% from the last close, and Ticker Nerd's factor model ranks Cogent Biosciences, Inc. 34 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the COGT stock forecast for 2030?

No analyst covering Cogent Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COGT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $45 to $62 over the next 12 months.

How has COGT stock performed over the past year?

Cogent Biosciences, Inc. returned +110.3% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cogent Biosciences, Inc. do?

Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases.

What is the latest news on COGT?

The most recent item we track (GlobeNewsWire, 15 Sept 2026): "Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)". Cogent Biosciences announced that the FDA has accepted its New Drug Application for bezuclastinib in patients with advanced systemic mastocytosis (AdvSM). The application is supported by positive results from the APEX pivotal trial, which demonstrated clinically meaningful responses and evidence of disease modification.

Company

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Its current programs center on targeted small-molecule medicines designed to address specific molecular drivers of serious conditions, with a lead emphasis on KIT-mutated diseases such as systemic mastocytosis and certain gastrointestinal stromal tumors. The company is also advancing additional research programs across other genetically driven cancers and rare diseases, including areas involving FGFR, ErbB2, PI3Kα, KRAS, and JAK2 alterations. Cogent Biosciences works within the biopharmaceutical and precision oncology markets, where highly selective therapies are used to match treatment to disease biology. Headquartered in Waltham, Massachusetts, Cogent Biosciences concentrates on translating molecular insights into specialized treatment options for patients with unmet medical needs.

CEO Mr. Andrew R. Robbins M.B.A. · 258 employees · United States · https://www.cogentbio.com